Can I Take Resveratrol with Farxiga (Dapagliflozin)?

The short answer, with its boundary

Farxiga (dapagliflozin) is cleared mainly through UGT1A9-mediated glucuronidation, with a smaller contribution from CYP3A4, according to its prescribing information. Resveratrol inhibits both of those enzymes in laboratory studies, and it has a modest glucose-lowering effect of its own in people with diabetes (pooled data from 11 randomized trials, weighted mean fasting glucose difference −0.29 mmol/L versus placebo) (Liu 2014). No published study has combined the two agents in humans, so the size of any real-world interaction is unverified and the guidance below is inference from separate lines of evidence rather than direct proof.

How each substance works

Farxiga blocks the sodium-glucose cotransporter 2 (SGLT2) in the kidney's proximal tubule, causing excess glucose to pass into the urine instead of being reabsorbed into the blood. Dapagliflozin was first approved by the FDA for type 2 diabetes and later gained expanded indications for heart failure with reduced ejection fraction, based on the DAPA-HF trial (N=4,744) (McMurray 2019), and for chronic kidney disease, based on the DAPA-CKD trial (N=4,304) (Heerspink 2020). The FDA label describes dapagliflozin's glucose-lowering and mild diuretic effects; exact magnitude figures (HbA1c change, blood pressure change) vary by trial population and should be confirmed against the current label rather than treated as a fixed number for an individual patient (per the manufacturer's current prescribing information).

Resveratrol (3,5,4′-trihydroxystilbene) is a stilbenoid polyphenol studied largely in preclinical models for effects on SIRT1 and AMPK, enzymes linked to insulin sensitivity and mitochondrial function (Baur 2006). In diabetic populations, meta-analyzed trial data show a small fasting-glucose reduction, but no significant effect in people without diabetes (Liu 2014). Resveratrol also binds estrogen receptor beta, with published binding-affinity work describing it as a mixed estrogen receptor agonist/antagonist that is far weaker than estradiol at the receptor (Bowers 2000); this is a resveratrol-specific property, unrelated to dapagliflozin.

The pharmacokinetic question: does resveratrol raise dapagliflozin levels?

Dapagliflozin is metabolized primarily by UGT1A9, with CYP3A4 playing a smaller role. In vitro enzyme-inhibition data summarized in a pharmacology review indicate that resveratrol can inhibit both CYP3A4 and UGT1A9 at low micromolar concentrations (Detampel 2012). A human volunteer study found that oral resveratrol altered activity of several drug-metabolizing enzymes at supplement-range doses, though that study did not test dapagliflozin specifically and its findings should not be read as a direct measurement of a resveratrol-dapagliflozin interaction (Chow 2010).

The closest real-world comparison in the dapagliflozin label is mefenamic acid, a UGT1A9 inhibitor that increased dapagliflozin exposure without requiring a dose adjustment; the exact percentage increase and clinical context should be confirmed directly against the current label text before being cited as a fixed figure (per the manufacturer's current prescribing information). Resveratrol's oral bioavailability is low because of rapid first-pass conjugation, which limits how much systemic enzyme inhibition it can sustain outside the gut wall. Put together, the plausible effect of typical-dose resveratrol on dapagliflozin blood levels is a modest increase, not a large one, but no study has measured this directly, so a specific percentage cannot be stated with confidence.

The pharmacodynamic question: do the glucose and fluid effects add up?

Dapagliflozin alone carries a relatively low hypoglycemia risk on its own, because its glucose-lowering effect diminishes once blood glucose falls below the renal reabsorption threshold. That protection weakens when dapagliflozin is combined with agents that lower glucose independent of that threshold, such as sulfonylureas. A trial combining dapagliflozin with glimepiride reported a meaningfully higher hypoglycemia rate than dapagliflozin alone in that trial population (Strojek 2011); resveratrol's own glucose-lowering effect is smaller than a sulfonylurea's, but adding it to an already glucose-lowering regimen is the scenario where added monitoring matters most.

Farxiga produces a mild osmotic diuresis through urinary glucose loss. Rodent studies have reported natriuretic properties for resveratrol, but human evidence for a clinically meaningful diuretic effect from oral supplement doses is lacking. Anyone taking a loop diuretic, or older adults during illness or hot weather, should watch for dizziness on standing, reduced urination, or unusual thirst if combining both.

What is established, what is plausible, and what is not established

Evidence-status interaction assessment: resveratrol + Farxiga (dapagliflozin)

A practical way to think about your own risk

Lower concern. Farxiga for heart failure or CKD, without a sulfonylurea or insulin, resveratrol at 150 to 250 mg/day. Mention it at your next routine visit and check glucose and kidney function as usual.

Moderate concern. Farxiga for type 2 diabetes with metformin or a DPP-4 inhibitor, resveratrol at 250 to 500 mg/day. Check fasting glucose weekly for the first month after starting the combination and keep a fast-acting carbohydrate source available.

Higher concern. Farxiga plus insulin or a sulfonylurea, resveratrol above 500 mg/day, or additional strong CYP3A4 inhibitors in the regimen (grapefruit juice, ketoconazole, clarithromycin). Do not start this combination without your prescriber's input and a specific monitoring plan.

Dose timing

Because gut-level enzyme inhibition is where resveratrol's effect on CYP3A4/UGT1A9 is strongest, separating the two by at least 2 hours (Farxiga with breakfast, resveratrol later in the day) is a reasonable low-effort precaution. It is not proven necessary for safety, but it reduces the theoretical window of peak co-inhibition. If you have already been taking both at the same time for weeks without symptoms of low blood sugar, dizziness, or unusual lab changes, the practical risk appears low; still mention the combination to your prescriber so it is documented and monitored going forward.

Monitoring if you combine them

No formal guideline addresses resveratrol and dapagliflozin together. The schedule below draws on standard SGLT2 inhibitor follow-up practice and the general obesity/metabolic monitoring framework in the Endocrine Society's 2022 guideline, adapted for this specific combination rather than quoted from it directly.

Baseline: fasting glucose, HbA1c, basic metabolic panel (sodium, potassium, creatinine, eGFR), seated and standing blood pressure, and a full list of current supplements and medications.

Weeks 2 to 4: fasting glucose and blood pressure; ask about dizziness on standing, unusual thirst, or reduced urination. A fasting glucose below 70 mg/dL or a systolic drop of more than 10 mmHg from baseline is a reason to reduce or pause the supplement first, then reassess with your prescriber.

Weeks 6 to 8: repeat basic metabolic panel and eGFR. An initial eGFR dip of up to roughly 10% after starting an SGLT2 inhibitor is expected and generally reflects hemodynamic changes rather than kidney injury; a larger or progressive drop warrants re-evaluation (Heerspink 2020).

Ongoing: routine SGLT2 inhibitor follow-up every 3 to 6 months, with any new supplement, antibiotic, or antifungal flagged for reassessment of the CYP3A4/UGT1A9 picture.

What the evidence does not say

No randomized or observational human study has evaluated resveratrol taken together with dapagliflozin, and no case series describing this specific combination was identified. Claims that circulate about "minor" interaction ratings for this pair, or specific numeric interaction quotes attributed to review articles, could not be verified against a matching primary source during this review and have been removed rather than presented as fact. Readers and clinicians should treat any precise interaction percentage for this specific combination as unverified until a direct study or an authoritative interaction database entry can be checked.

When to contact your doctor

• Fingerstick glucose consistently below 70 mg/dL
• Persistent dizziness, especially when standing up
• Signs of a urinary tract infection (burning, frequency, cloudy urine); SGLT2 inhibitors already raise UTI risk
• Nausea, vomiting, or abdominal pain, which can signal euglycemic diabetic ketoacidosis, a rare but serious risk with any SGLT2 inhibitor
• New or worsening genital yeast infection symptoms

Do not adjust your Farxiga dose on your own, and if you decide to stop either agent, talk to your prescriber first about the sequence to avoid rebound hyperglycemia or unnecessary lab repeats.